Helicobacter pylori, or H. pylori, is one of the world’s most common chronic bacterial infections. Estimated to impact 4.4 billion individuals globally, H. pylori affects 35% to 89% of children, depending the on the geographic region in...
Autoimmune Liver Disease Testing - Mayo Clinic Laboratories
Our panel evaluates smooth muscle antibodies (SMA), antinuclear antibodies (ANA), and antimitochondrial antibodies (AMA) for patients with suspected autoimmune liver disease, specifically type 1 AIH or PBC or with liver disease of unknown...
Hepatocellular carcinoma - Insights
Hepatocellular carcinoma (HCC) is the third leading cause of death from cancer in the world. While HCC can be effectively treated in its early stages, most patients are not diagnosed until they are symptomatic and at higher grades and...
Emergency toxicology - Insights
Mayo Clinic Laboratories’ emergency toxicology testing can help providers manage overdose by clarifying whether symptoms are due to the presence of drugs.
Bone and Soft Tissue Pathology Services at Mayo Cinic Laboratories
At Mayo Clinic, we excel in our approach to work collaboratively with radiology, surgery, and clinical practice to bring the highest quality.
Cytopathology Services at Mayo Clinic Laboratories
Pathologists from across the world send cases for the cytopathology section at Mayo Clinic to review. Learn more.
Test panel guides diagnosis of early onset IBD: Ann Moyer, M.D., Ph.D. - Insights
Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' test panel provides comprehensive evaluation of patients with suspected monogenic early onset inflammatory bowel disease, or IBD. Accurate diagnosis is key to guiding therapy...
In 2020, Mayo Clinic Laboratories launched more than 100 new tests. Driven by a patient-centered philosophy, our experts, laboratories, and facilities make it possible to develop new tests that transform medicine worldwide.
New tests launched in April - Insights
In April 2022, Mayo Clinic Laboratories announced fourteen new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
Assay stratifies pregnant women's preeclampsia risk: Joshua Bornhorst, Ph.D. - Insights
Joshua Bornhorst, Ph.D., explains how Mayo Clinic Laboratories' unique assay identifies pregnant women at risk of developing preeclampsia with severe features. Test results can guide clinical management, to safeguard maternal and neonatal...